People who stay on the lowest starting doses of GLP-1 drugs for months may still lose weight, according to research published in Biology Methods & Protocols on August 31 and reported by Healthline. The finding overlaps with what social media and celebrity coverage calls microdosing, though the study did not establish that anyone in it was microdosing on purpose.

The drugs are semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), both of which are normally escalated to a higher maintenance dose over several months. Using them outside their approved dosing schedules is not FDA- or manufacturer-approved.

Two drugs, two trajectories

The researchers pulled electronic health records from 814 people on sustained low dose semaglutide, defined as at least three 0.25 mg doses spanning at least six months, and 1,016 people on sustained low dose tirzepatide at 2.5 mg over the same stretch. At one year, the low dose tirzepatide group saw around 5.5% weight loss and the low dose semaglutide group around 2.2%.

The more useful number is the head to head. After matching on age, sex, BMI and type 2 diabetes status, people on low dose semaglutide lost about 1.7% of body weight against roughly 12% for those escalated to high dose, which is the honest scale of what a starter dose buys you.

Side effects at the low end

Co-author Venky Soundararajan, PhD, of nference told Healthline that low dose tirzepatide was associated with modestly more weight loss, while the adverse event pattern significantly favored low dose semaglutide. Compared with patients escalating to conventional doses, sustained lowest dose semaglutide was associated with lower 24-month rates of constipation (23.3% versus 36.3%), nausea (39.7% versus 50.1%) and low blood pressure (1.7% versus 5.4%).

He framed the question as precision obesity care: not how much weight a drug can produce, but the lowest dose that meets a patient's cardiometabolic goals with the best tolerability. Weight reductions, he said, remained evident through 15 months of follow-up.

The plateau clinicians see

Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center in Fountain Valley, California, who was not involved in the study, said he has seen meaningful weight loss at starter doses in his own practice. He also said many patients eventually stop losing on the lowest dose, and most will need some degree of escalation to keep going.

The lowest effective dose question

This is health records data, not a trial, and it cannot say whether anyone chose to stay low or simply never moved up. What it does put numbers on is a trade-off the field has been discussing anecdotally: modest sustained loss in the 2 to 7% range against a lower side effect burden, with the appropriate dose still a matter between patient and clinician.